A lack of head-to-head randomized controlled trials (RCTs) comparing chemotherapy, anti-angiogenesis drugs, and immunotherapies leaves uncertainty regarding optimal first-line treatment for advanced NSCLC patients with negative PD-L1 expression. The gene discussed is CD274; the disease is non-small cell lung carcinoma.